Longitudinal Monitoring of Clinically Significant Liver Fibrosis in MASLD in the Era of Novel Therapeutics: Challenges, Reproducibility, and Clinical Utility of Non-Invasive Tests
Resmetirom and semaglutide are approved for non-cirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with F2–F3 fibrosis. Guidance increasingly relies on non-invasive tests (NITs) rather than repeat biopsy to monitor response. Serial changes in FIB-4, vibration-controlled transient elastography (VCTE) and magnetic resonance elastography are prognostic for fibrosis progression and liver-related events. However, short-term variability is substantial. VCTE stiffness showed a reproducibility coefficient above 55%, whereas enhanced liver fibrosis (ELF) was markedly more stable. The consensus 30% stiffness-reduction threshold therefore lies within measurement noise. Weight loss and falling aminotransferases may shift NITs independently of fibrosis regression, and FIB-4–stiffness discordance affects about 30% of patients. Serial NITs are valuable prognostic tools but insufficient as stand-alone response measures. Standardised acquisition, variability-aware thresholds and paired complementary tests are advisable pending validation against histology and clinical outcomes.
Authors
- Mohammadjavad Sotoudeheian (ORCID: https://orcid.org/0000-0001-7181-2944)
Publication Details
- Journal
- Preprints.org
- Published
- 2026-11-13
- DOI
- https://doi.org/10.20944/preprints202611.1440.v1
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- preprint